Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study.

Cardiovascular research - 8 Jul 2025

Gagnon Eloi, Gill Dipender, Bourgault Jérôme, Gobeil Émilie, Mitchell Patricia L, Girard Arnaud, Paulin Audrey, Couture Christian, Bossé Yohan, Thériault Sébastien, Mathieu Patrick, Vohl Marie-Claude, Tchernof André, Ray Kausik K, Kastelein John J P, Arsenault Benoit J

Abstract excerpt

AIMS: RNA interference therapies targeting liver expression of the gene proprotein convertase subtilisin/kexin type 9 (PCSK9) lower LDL-cholesterol (LDL-C) and apolipoprotein B (apoB) levels. As opposed to monoclonal antibodies, which neutralise PCSK9 circulating protein, their effect on atherosclerotic cardiovascular disease (ASCVD) outcomes is unknown. We used genetic variants in the PCSK9 locus influencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein B-100
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Dyslipidemias

Share to Mendelian Randomization Analysis

Share to Proprotein Convertase 9

Share to RNA Interference

Share to Serine Proteinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40347490
DOI: 10.1093/cvr/cvaf078
PMCID: PMC12236069

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study.PMID 40347490Read ↗

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four AncestriesSemantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome EditingSemantic proximity Read ↗

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy EraSemantic proximity Read ↗

Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.Semantic proximity Read ↗

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesSemantic proximity Read ↗

A NATUrally Randomized trial Evaluating a vaccine-like strategy to lower LDL by inhibiting PCSK9 on the lifetime risk of major cardiovascular events (NATURE-PCSK9)Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials.Semantic proximity Read ↗

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.